Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Hagedorn

Pain Medicine Rochester, MN Medical Doctor

NPI 1972977098 CMS profile 1378529

200 1St St Sw, Rochester, MN 55905

Open in the dashboard

General payments

$82,601

236 records reported · program years 2019–2025

Research payments

$503

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$90,353 paid to institutions, not to them · program years 2022–2024

Through program year 2025, Jonathan Hagedorn of Rochester, MN is reported in the CMS Open Payments database as having received $82,601 across 236 general payments and $503 in research payments paid to them. Separately, studies naming them as principal investigator received $90,353 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $142 1
2024 General $116 1
2023 General $14,152 15
2022 General $41,609 94
2021 General $21,172 99
2020 General $4,048 13
2020 Research $410 1
2019 General $1,362 13
2019 Research $93 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Hagedorn
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Jonathan Hagedorn were reported at $142. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Jonathan Hagedorn Pain Medicine median Middle half National median
2019 $1,362 $506 $144–$1,566 $163
2020 $4,048 $315 $96–$934 $114
2021 $21,172 $452 $134–$1,237 $132
2022 $41,609 $475 $124–$1,407 $149
2023 $14,152 $480 $136–$1,384 $160
2024 $116 $521 $164–$1,511 $164
2025 $142 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nevro Corp. $53,676 96 payments
  2. Abbott Laboratories $10,010 88 payments
  3. NeuroOne Medical Technologies Corporation $5,250 2 payments
  4. Medtronic, Inc. $4,648 22 payments
  5. Boston Scientific Corporation $4,498 14 payments
  6. Saluda Medical Americas, Inc. $3,469 5 payments
  7. Stratus Medical, LLC $750 1 payment
  8. Medtronic USA, Inc. $203 2 payments
  9. DePuy Synthes Sales Inc. $32 1 payment
  10. Almatica Pharma LLC $27 2 payments
  11. Other $38 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $27,756 24 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $24,143 18 payments
  3. Travel and Lodging $17,180 43 payments
  4. Food and Beverage $8,722 147 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,800 4 payments
Products named General payments · program years 2019–2025
  1. Omnia $49,089 69 payments
  2. Proclaim IPG $5,042 44 payments
  3. INTELLIS ADAPTIVESTIM $3,671 5 payments
  4. Evoke SCS $3,469 5 payments
  5. GENERAL - PAIN MANAGEMENT $2,791 4 payments
  6. Senza Spinal Cord Stimulation System $2,065 14 payments
  7. Senza $1,817 12 payments
  8. Proclaim DRG IPG $1,315 3 payments
  9. PROCLAIM $1,266 10 payments
  10. PRODIGY $1,114 4 payments
  11. Other $5,524 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic USA, Inc. $410 1 payment
  2. Saluda Medical Americas, Inc. $93 4 payments

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$28,211

Of which drugs: $86

Medicare patients

205

Average age 73

Services billed

548

99 women, 106 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 71%
Ischemic heart disease 33%
Chronic kidney disease 29%
Depression 29%
Diabetes 25%
Atrial fibrillation 22%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 23 96 $74

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

241 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record